Core Scientific, Inc. CORZ
17.34
(0.79)
(4.36%)
as of 25 Sep
- Market cap
- $5.9B
- P/E
- 0.0×
Follow CORZ
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
18.91 | 13.62 | 14.52 | 17.10 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(439.83) | 19.33 | 30.26 | 41.95 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
24.27 | 13.61 | 16.86 | 18.91 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
20.54 | 8.42 | 19.34 | 45.48 | |
EV/FCF |
(8.95) | (10.37) | (11.76) | (17.94) | |
Quick Ratio |
0.71 | 0.40 | 0.40 | 0.68 | |
Current Ratio |
0.89 | 0.55 | 1.15 | 1.58 | |
Net Debt/EBITDA |
(38.47) | 0.01 | (7.77) | (18.04) | |
Debt/Assets |
81.75% | 34.59% | 45.17% | 46.12% | |
Debt/Equity |
(1.78) | (0.81) | (1.10) | (0.94) | |
Asset Turnover |
0.12 | 0.15 | 0.17 | 0.21 | |
Operating CF/Net income |
0.02 | (0.73) | (0.27) | (0.92) | |
Capex/Depreciation |
(46.68) | (17.99) | (14.83) | (10.85) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
30.08% | 38.91% | 0.00% | 85.51% | |
Intangible Assets out of Total Assets |
0.04 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
11.11% | 15.41% | 35.02% | 36.92% | |
Graham Net Nets |
(0.63) | (0.60) | (0.52) | (0.41) | |
Graham Number |
26.64 | 18.75 | 9.65 | 14.30 | |
Earnings Yield |
(16.57%) | (25.84%) | (9.38%) | (14.30%) | |
Free Cash Flow Yield |
(14.35%) | (9.63%) | (9.88%) | (6.16%) | |
Revenue per Share |
0.50 | 0.36 | 0.25 | 0.25 | |
Operating CF per Share |
(0.06) | 0.77 | 0.48 | 0.43 | |
Capex per Share |
(2.45) | (1.20) | (0.86) | (0.81) | |
Free Cash Flow per Share |
(2.51) | (0.42) | (0.38) | (0.38) | |
Cash per Share |
5.95 | 3.30 | 0.98 | 1.42 | |
Shareholders Equity per Share |
(7.44) | (4.04) | (3.03) | (3.54) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(7.44) | (4.04) | (3.03) | (3.54) | |
Free Cash Flow |
(815.09) | (136.77) | (120.26) | (122.61) | |
Working Capital |
(294.15) | (1,206.95) | 114.14 | 391.17 | |
Capital Expenditures |
(796.16) | (386.65) | (273.32) | (258.84) | |
Net Current Asset Value |
(5,233.20) | (2,920.42) | (2,414.85) | (2,362.91) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
4.85 | 3.36 | 3.43 | 3.19 | |
Net Profit Margin |
(658.39%) | (297.14%) | (723.03%) | (181.88%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
163.71 | 112.59 | 72.69 | 109.34 | |
Average Assets |
3,617.77 | 2,347.47 | 1,911.80 | 1,608.92 | |
Average Common Equity |
(1,742.02) | (743.60) | (952.89) | (928.68) |
Columns are period end dates